New Advances in Nanoparticles-Based Drug Delivery

A special issue of Nanomaterials (ISSN 2079-4991). This special issue belongs to the section "Biology and Medicines".

Deadline for manuscript submissions: closed (20 November 2023) | Viewed by 2216

Special Issue Editor


E-Mail Website
Guest Editor
1. CPIRN-UDI/IPG—Centro de Potencial e Inovação em Recursos Naturais, Unidade de Investigação para o Desenvolvimento do Interior do Instituto Politécnico da Guarda, Avenida Dr. Francisco de Sá Carneiro, No. 50, 6300-559 Guarda, Portugal
2. CICS-UBI—Health Sciences Research Centre, Faculdade de Ciências da Saúde da Universidade da Beira Interior, Av. Infante D. Henrique, 6201-506 Covilhã, Portugal
Interests: nanomaterials; nanomedicine; photothermal therapy; drug delivery; theragnostic nanomaterials; gold-based nanostructures; stimuli-responsive nanoparticles
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Since Richard Feynman’s talk “There’s plenty of room at the bottom”, several researchers have been exploring the application of nanotechnology to several areas such as materials engineering, electronics, and medicine. Particularly in drug delivery applications, nanoparticles can enhance the drug's aqueous solubility, avoid premature degradation and clearance from the body, reduce off-target interaction, as well as increase the drug bioavailability, leading to an enhanced therapeutic effect. Moreover, the utilization of “smart materials” can be important for developing stimuli-responsive drug delivery nanoparticles, enabling the recognition of target sites, and overcoming different biological barriers. Therefore, nanoparticles open the way for the development of novel and more effective therapies with tailored pharmacokinetics and pharmacodynamics. Such advantages can also play an important role in the pharmaceutical industry for drug repurposing.

Therefore, this Special Issue aims to cover the application of nanoparticle-based drug delivery systems, both organic and inorganic nanostructures, in the biomedical field. We welcome the submission of works reporting the development and application of cutting-edge nanomaterials, as well as review articles that offer a balanced view of the current state-of-the-art nanoparticles-based drug delivery systems.

Potential topics include but are not limited to:

  • Polymeric, lipidic, and inorganic-based nanoparticles as drug delivery systems;
  • Targeted drug delivery using nanoparticles;
  • Stimuli-responsive drug delivery systems;
  • Combinatorial drug delivery mediated by nanomaterials;
  • Nanoparticle drug delivery to the brain;
  • Nanoparticle drug delivery to cancer;
  • Nanoparticle application as theragnostic systems.

Dr. André Ferreira Moreira
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Nanomaterials is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • inorganic nanomaterials
  • organic nanoparticles
  • targeted drug delivery
  • surface functionalization
  • stimuli-responsive release
  • drug release kinetics
  • oral drug delivery
  • intravenous administration
  • nanomedicines
  • smart nanomaterials

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

18 pages, 1031 KiB  
Article
Polyoxometalate-Decorated Gold Nanoparticles Inhibit β-Amyloid Aggregation and Cross the Blood–Brain Barrier in a µphysiological Model
by Marta Perxés Perich, Sujey Palma-Florez, Clara Solé, Sara Goberna-Ferrón, Josep Samitier, Pedro Gómez-Romero, Mònica Mir and Anna Lagunas
Nanomaterials 2023, 13(19), 2697; https://doi.org/10.3390/nano13192697 - 3 Oct 2023
Viewed by 1876
Abstract
Alzheimer’s disease is characterized by a combination of several neuropathological hallmarks, such as extracellular aggregates of beta amyloid (Aβ). Numerous alternatives have been studied for inhibiting Aβ aggregation but, at this time, there are no effective treatments available. Here, we developed the tri-component [...] Read more.
Alzheimer’s disease is characterized by a combination of several neuropathological hallmarks, such as extracellular aggregates of beta amyloid (Aβ). Numerous alternatives have been studied for inhibiting Aβ aggregation but, at this time, there are no effective treatments available. Here, we developed the tri-component nanohybrid system AuNPs@POM@PEG based on gold nanoparticles (AuNPs) covered with polyoxometalates (POMs) and polyethylene glycol (PEG). In this work, AuNPs@POM@PEG demonstrated the inhibition of the formation of amyloid fibrils, showing a 75% decrease in Aβ aggregation in vitro. As it is a potential candidate for the treatment of Alzheimer’s disease, we evaluated the cytotoxicity of AuNPs@POM@PEG and its ability to cross the blood–brain barrier (BBB). We achieved a stable nanosystem that is non-cytotoxic below 2.5 nM to human neurovascular cells. The brain permeability of AuNPs@POM@PEG was analyzed in an in vitro microphysiological model of the BBB (BBB-on-a-chip), containing 3D human neurovascular cell co-cultures and microfluidics. The results show that AuNPs@POM@PEG was able to cross the brain endothelial barrier in the chip and demonstrated that POM does not affect the barrier integrity, giving the green light to further studies into this system as a nanotherapeutic. Full article
(This article belongs to the Special Issue New Advances in Nanoparticles-Based Drug Delivery)
Show Figures

Graphical abstract

Back to TopTop